New drug review processes would be accelerated and completed in 120 days in response to a US plan to raise pharmaceutical tariffs, the Ministry of Health and Welfare said yesterday.
Food and Drug Administration (FDA) Deputy Director-General Wang Der-yuan (王德原) yesterday told a news conference that measures have been taken to optimize new medicine review processes and help pharmaceutical companies obtain drug permit licenses as soon as possible.
Such processes normally take about 360 days to complete, if the new medicine is a new chemical entity (NCE) — a drug with new chemicals as principal components — or a drug made from biological sources, also known as biologics.
Photo: AP
However, NCEs or biologics considered important for pediatric treatments and serious diseases, as well as breakthrough therapies can have their review prioritized, with the process shortened to 240 days, he said.
If an NCE or a biologic has been approved in two of the US, the EU or Japan, it is qualified for a “type 1 express review” and can have its review completed as fast as in 180 days, Wang said.
If it has been approved in the three areas with identical data on chemistry, manufacturing and controls, it is qualified for a “type 2 express review” and its review process could be completed in 120 days, he added.
The ministry would also continue to encourage pharmaceutical companies to diversify sources of bulk drugs or active pharmaceutical ingredients so that they would not rely on a single supplier, he said.
China and India are the two major sources of bulk drugs used in Taiwan’s pharmaceutical industry, he said.
The FDA has requested pharmaceutical companies to evaluate whether they should find more bulk drug sources, Wang said, adding that the agency would prioritize the review of new medicines relying on a single source.
Pharmaceutical companies should also use domestically made bulk drugs, although they are mostly more expensive and less adopted, he said.
The administration has compiled an inventory of all US-made pharmaceutical products and sent a notice to their permit license holders to fully understand the medicine supply chain situation and properly boost domestic medicine stocks, he said.
It would also check stocks of primary medicines, such as anti-cancer drugs, orphan drugs and biologics to promptly initiate an investigation and evaluation whenever there is a potential shortage, he said.
The FDA would ask manufacturers of substitute medicines to increase production, or launch a drug import or manufacturing project, if necessary, he said.
Pharmaceutical companies can propose price adjustments to stabilize the market if changes in the global supply chain cause a surge in drug production costs, he said.
The ministry would continue to promote the application of generic drugs and biosimilars — biologics with similar structure and functions of a reference biologic made by another company — to bolster domestically made new medicines, Wang added.
Considering that most countries issue more than five denominations of banknotes, the central bank has decided to redesign all five denominations, the bank said as it prepares for the first major overhaul of the banknotes in more than 24 years. Central bank Governor Yang Chin-lung (楊金龍) is expected to report to the Legislative Yuan today on the bank’s operations and the redesign’s progress. The bank in a report sent to the legislature ahead of today’s meeting said it had commissioned a survey on the public’s preferences. Survey results showed that NT$100 and NT$1,000 banknotes are the most commonly used, while NT$200 and NT$2,000
The Centers for Disease Control (CDC) yesterday reported the first case of a new COVID-19 subvariant — BA.3.2 — in a 10-year-old Singaporean girl who had a fever upon arrival in Taiwan and tested positive for the disease. The girl left Taiwan on March 20 and the case did not have a direct impact on the local community, it said. The WHO added the BA.3.2 strain to its list of Variants Under Monitoring in December last year, but this was the first imported case of the COVID-19 variant in Taiwan, CDC Deputy Director-General Lin Ming-cheng (林明誠) said. The girl arrived in Taiwan on
South Korea is planning to revise its controversial electronic arrival card, a step Taiwanese officials said prompted them to hold off on planned retaliatory measures, a South Korean media report said yesterday. A Yonhap News Agency report said that the South Korean Ministry of Foreign Affairs is planning to remove the “previous departure place” and “next destination” fields from its e-arrival card system. The plan, reached after interagency consultations, is under review and aims to simplify entry procedures and align the electronic form with the paper version, a South Korean ministry official said. The fields — which appeared only on the electronic form
The Ministry of Foreign Affairs (MOFA) is suspending retaliation measures against South Korea that were set to take effect tomorrow, after Seoul said it is updating its e-arrival system, MOFA said today. The measures were to be a new round of retaliation after Taiwan on March 1 changed South Korea's designation on government-issued alien resident certificates held by South Korean nationals to "South Korea” from the "Republic of Korea," the country’s official name. The move came after months of protests to Seoul over its listing of Taiwan as "China (Taiwan)" in dropdown menus on its new online immigration entry system. MOFA last week
RSS